Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody-Reference-Cited by-同舟云学术

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

Published:2016-03-18 Issue:6279 Volume:351 Page:1339-1342
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Corti Davide¹²,Misasi John³,Mulangu Sabue³,Stanley Daphne A.³,Kanekiyo Masaru³,Wollen Suzanne⁴,Ploquin Aurélie³,Doria-Rose Nicole A.³,Staupe Ryan P.³,Bailey Michael³,Shi Wei³,Choe Misook³,Marcus Hadar³,Thompson Emily A.³,Cagigi Alberto³,Silacci Chiara¹,Fernandez-Rodriguez Blanca¹,Perez Laurent¹,Sallusto Federica¹,Vanzetta Fabrizia²,Agatic Gloria²,Cameroni Elisabetta²,Kisalu Neville⁵,Gordon Ingelise³,Ledgerwood Julie E.³,Mascola John R.³,Graham Barney S.³,Muyembe-Tamfun Jean-Jacques⁵,Trefry John C.⁴,Lanzavecchia Antonio¹⁶,Sullivan Nancy J.³

Affiliation:

1. Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland.

2. Humabs BioMed SA, 6500 Bellinzona, Switzerland.

3. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.

4. U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.

5. National Institute for Biomedical Research, National Laboratory of Public Health, Kinshasa B.P. 1197, Democratic Republic of the Congo.

6. Institute of Microbiology, ETH Zürich, CH-8093 Zürich, Switzerland.

Abstract

Antibodies block Ebola virus entry The recent Ebola virus outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of the 1995 Kikwit outbreak and demonstrated their therapeutic efficacy in Ebola virus–infected macaques. In fact, one antibody protected macaques when it was given up to 5 days after infection. Misasi et al. solved the crystal structures of fragments of the two antibodies bound to the Ebola virus glycoprotein (GP), which mediates viral cell entry. The two antibodies targeted different regions of GP, but in both cases blocked steps required for viral entry. Science , this issue pp. 1339 & 1343

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference24 articles.

1. Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections

2. Ebola haemorrhagic fever in Zaire, 1976;Burke J.;Bull. World Health Organ.,1978

3. Gulland A. Institutional failure led to Ebola outbreak “spiralling out of control ” says MSF. BMJ 350 h1619 (2015).

4. Ebola virus outbreaks in Africa: Past and present

5. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies

Cited by 353 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A method for screening CDV microneutralization activity in microvolume samples;Journal of Virological Methods;2024-04

2. Design of universal Ebola virus vaccine candidates via immunofocusing;Proceedings of the National Academy of Sciences;2024-02-06

3. Prevention and post-exposure management of occupational exposure to Ebola virus;The Lancet Infectious Diseases;2024-02

4. Neutralizing monoclonal antibodies against the Gc fusion loop region of Crimean–Congo hemorrhagic fever virus;PLOS Pathogens;2024-02-01

5. Humanized Antibodies. Modern Developments and Prospects for the Creation of Medical Protectors Against Biological Threads and Hazards;Journal of NBC Protection Corps;2024-01-08